



Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(d) On September 19, 2006, Jack Kaye was appointed to the Board of Directors of Keryx Biopharmaceuticals, Inc. (“Keryx”) by unanimous vote of the directors. Mr. Kaye was also appointed to the Audit Committee of the Board and will serve as the chairperson. There are no arrangements or understandings between Mr. Kaye and any other person pursuant to which Mr. Kaye was appointed to the Board. Since January 1, 2005, Mr. Kaye has not entered into any transaction in which he has a direct or indirect material interest and in which Keryx or any subsidiary of Keryx is also a party, and Mr. Kaye is not currently considering any such transactions. The text of a press release announcing the appointment of Mr. Kaye is furnished as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On September 20, 2006, Keryx issued the press release attached as Exhibit 99.1 hereto announcing the appointment of Mr. Kaye to Keryx’s Board of Directors.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

The following exhibit is furnished as a part of this report:

Exhibit Number	Description
99.1	Press Release dated September 20, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.
(Registrant)

Date: September 19, 2006

By: /s/ Ronald C. Renaud, Jr.

Ronald C. Renaud, Jr.
Senior Vice President,
Chief Financial Officer,
Secretary and Treasurer

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated September 20, 2006.